STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Tarsus to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in two upcoming investor conferences in September 2025. Management will present at the Wells Fargo 20th Annual Healthcare Conference on September 3rd at 9:30 a.m. ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 9th at 10:30 a.m. ET.

Investors can access live webcasts of both presentations through the events section of the Tarsus website. Replay recordings will be available within 48 hours and archived for a limited time.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

  • Wells Fargo 20th Annual Healthcare Conference on Wednesday, September 3rd, at 6:30 a.m. PT / 9:30 a.m. ET
  • H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9th, at 7:30 a.m. PT / 10:30 a.m. ET

Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com


FAQ

When is Tarsus Pharmaceuticals (TARS) presenting at the Wells Fargo Healthcare Conference 2025?

Tarsus will present at the Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025 at 9:30 a.m. ET.

When is the H.C. Wainwright Conference presentation for Tarsus (TARS)?

Tarsus will present at the H.C. Wainwright Global Investment Conference on Tuesday, September 9th, 2025 at 10:30 a.m. ET.

How can investors access Tarsus (TARS) conference presentations?

Investors can access live webcasts through the events section of the Tarsus website. Replays will be available within 48 hours and archived for a limited time.

Which investor conferences is Tarsus Pharmaceuticals (TARS) attending in September 2025?

Tarsus is attending the Wells Fargo 20th Annual Healthcare Conference on September 3rd and the H.C. Wainwright 27th Annual Global Investment Conference on September 9th.
Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

TARS Rankings

TARS Latest News

TARS Latest SEC Filings

TARS Stock Data

3.39B
39.69M
3.18%
118.17%
16.41%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
IRVINE